MedTrace Logo

Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study

NCT04912024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 458

Last updated 2022-08-12

No results posted yet for this study

Summary

Retrospective, multicenter, comparative, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Renal Disease or Acute Kidney Injury.

Conditions

Interventions

DEVICE

Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System

Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD

DEVICE

Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems

Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD

Sponsors & Collaborators

  • Outset Medical

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-15
Primary Completion
2022-06-15
Completion
2022-06-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912024 on ClinicalTrials.gov